2021
Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).
Yu Y, Schöder H, Kang J, McBride S, Tsai C, Chen L, Zakeri K, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Pfister D, Wong R, Riaz N, Lee N. Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC). Journal Of Clinical Oncology 2021, 39: 6060-6060. DOI: 10.1200/jco.2021.39.15_suppl.6060.Peer-Reviewed Original ResearchPostoperative PET/CTIntermediate risk factorsSquamous cell carcinomaHigh-risk factorsPET/CTPT3-4 diseasePositive surgical marginsEarly recurrenceSurgical marginsExtranodal extensionLymphovascular invasionPerineural invasionRisk factorsOral cavityPostoperative radiotherapyOverall survivalPostoperative radiationPET/CT planningDistant metastasis-free survivalImproved disease-free survivalClinicopathologic risk factorsClose surgical marginsDisease-free survivalSalvage therapyDistant recurrence
2015
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal Of Clinical Oncology 2015, 33: 701-708. PMID: 25605861, PMCID: PMC4334774, DOI: 10.1200/jco.2014.57.6298.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalDNA, NeoplasmFemaleGene Expression Regulation, NeoplasticGenomicsHumansKaplan-Meier EstimateMiddle AgedMolecular Targeted TherapyProportional Hazards ModelsReceptor, ErbB-2TranscriptomeTrastuzumabConceptsRelapse-free survivalImmune function genesAdjuvant trastuzumab trialsArm BTrastuzumab trialsHazard ratioArm AHuman epidermal growth factor receptorClinicopathologic risk factorsProportional hazard ratiosEpidermal growth factor receptorGrowth factor receptorAdjuvant trastuzumabC patientsCombination chemotherapyClinical outcomesRisk factorsBreast cancerPatientsTrastuzumabPredictive signatureFunction genesChemotherapyGene enrichmentFactor receptor
2012
Role of excision repair cross‐complementation 1 expression as a prognostic marker for response to radiotherapy in early‐stage laryngeal cancer
Johung K, Rewari A, Wu H, Judson B, Contessa JN, Haffty BG, Decker RH. Role of excision repair cross‐complementation 1 expression as a prognostic marker for response to radiotherapy in early‐stage laryngeal cancer. Head & Neck 2012, 35: 852-857. PMID: 22740347, PMCID: PMC5723082, DOI: 10.1002/hed.23041.Peer-Reviewed Original ResearchConceptsERCC1 expressionOverall survivalExcision repair crossLocal controlT classificationLaryngeal cancerEarly-stage laryngeal cancerLaryngeal squamous cell carcinomaClinicopathologic risk factorsHigh ERCC1 expressionPlatinum-based chemotherapySquamous cell carcinomaWorse survivalCell carcinomaPrognostic valueStandard radiotherapyPrognostic markerRisk factorsEffective treatmentImmunohistochemical analysisTissue microarrayStage IRadiotherapy resistanceMultivariate analysisRadiotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply